| Joni H Hansson, MD | |
|
136 Sherman Ave, Suite 405, New Haven, CT 06511-5238 | |
| (203) 787-0117 | |
| (203) 777-3559 |
| Full Name | Joni H Hansson |
|---|---|
| Gender | Female |
| Speciality | Nephrology |
| Experience | 35 Years |
| Location | 136 Sherman Ave, New Haven, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760478077 | NPI | - | NPPES |
| 001319343 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 31924 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Shoreline Dialysis Center | Branford, CT | Dialysis facility |
| New Haven Home Dialysis | New haven, CT | Dialysis facility |
| Yale-new Haven Hospital | New haven, CT | Hospital |
| Bridgeport Hospital | Bridgeport, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Metabolism Associates Pc | 2668466244 | 11 |
News Archive
Specialty pharmaceutical company LEO Pharma today announced that findings from a Phase III study evaluating PEP005 (ingenol mebutate) Gel 0.05% to treat actinic keratosis (AK), a common pre-cursor to skin cancer, were presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) (Scientific Session Poster Discussion: P105). Results from REGION-I demonstrated treatment with PEP005 Gel once daily for 2 consecutive days.
The Georgia Institute of Technology and Micron Biomedical have been awarded $2.5 million in grants from the Bill & Melinda Gates Foundation to advance the development of dissolvable microneedle patches for polio immunization. The patches will be studied to evaluate their potential role as part of the worldwide efforts to eradicate polio.
Leaders in healthcare and the medical technology industry will bring you an in-depth look at Connected Health as emerging solutions can create real time feedback loops between patients and providers, whether in a hospital or clinic, at home, in the workplace or on the go.
Researchers have developed a three-dimensional 'organ on a chip' which enables real-time continuous monitoring of cells, and could be used to develop new treatments for disease while reducing the number of animals used in research.
Geron Corporation today announced the presentation of data from the clinical trial of imetelstat (GRN163L), the company's telomerase inhibitor drug, in combination with paclitaxel and bevacizumab in patients with breast cancer at the 2010 American Society of Clinical Oncology annual meeting in Chicago.
› Verified 3 days ago
| Entity Name | Yale University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205822236 PECOS PAC ID: 9436061736 Enrollment ID: O20031105000015 |
News Archive
Specialty pharmaceutical company LEO Pharma today announced that findings from a Phase III study evaluating PEP005 (ingenol mebutate) Gel 0.05% to treat actinic keratosis (AK), a common pre-cursor to skin cancer, were presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) (Scientific Session Poster Discussion: P105). Results from REGION-I demonstrated treatment with PEP005 Gel once daily for 2 consecutive days.
The Georgia Institute of Technology and Micron Biomedical have been awarded $2.5 million in grants from the Bill & Melinda Gates Foundation to advance the development of dissolvable microneedle patches for polio immunization. The patches will be studied to evaluate their potential role as part of the worldwide efforts to eradicate polio.
Leaders in healthcare and the medical technology industry will bring you an in-depth look at Connected Health as emerging solutions can create real time feedback loops between patients and providers, whether in a hospital or clinic, at home, in the workplace or on the go.
Researchers have developed a three-dimensional 'organ on a chip' which enables real-time continuous monitoring of cells, and could be used to develop new treatments for disease while reducing the number of animals used in research.
Geron Corporation today announced the presentation of data from the clinical trial of imetelstat (GRN163L), the company's telomerase inhibitor drug, in combination with paclitaxel and bevacizumab in patients with breast cancer at the 2010 American Society of Clinical Oncology annual meeting in Chicago.
› Verified 3 days ago
| Entity Name | Metabolism Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861473787 PECOS PAC ID: 2668466244 Enrollment ID: O20040414001492 |
News Archive
Specialty pharmaceutical company LEO Pharma today announced that findings from a Phase III study evaluating PEP005 (ingenol mebutate) Gel 0.05% to treat actinic keratosis (AK), a common pre-cursor to skin cancer, were presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) (Scientific Session Poster Discussion: P105). Results from REGION-I demonstrated treatment with PEP005 Gel once daily for 2 consecutive days.
The Georgia Institute of Technology and Micron Biomedical have been awarded $2.5 million in grants from the Bill & Melinda Gates Foundation to advance the development of dissolvable microneedle patches for polio immunization. The patches will be studied to evaluate their potential role as part of the worldwide efforts to eradicate polio.
Leaders in healthcare and the medical technology industry will bring you an in-depth look at Connected Health as emerging solutions can create real time feedback loops between patients and providers, whether in a hospital or clinic, at home, in the workplace or on the go.
Researchers have developed a three-dimensional 'organ on a chip' which enables real-time continuous monitoring of cells, and could be used to develop new treatments for disease while reducing the number of animals used in research.
Geron Corporation today announced the presentation of data from the clinical trial of imetelstat (GRN163L), the company's telomerase inhibitor drug, in combination with paclitaxel and bevacizumab in patients with breast cancer at the 2010 American Society of Clinical Oncology annual meeting in Chicago.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joni H Hansson, MD 136 Sherman Ave, Suite 405, New Haven, CT 06511-5238 Ph: (203) 787-0117 | Joni H Hansson, MD 136 Sherman Ave, Suite 405, New Haven, CT 06511-5238 Ph: (203) 787-0117 |
News Archive
Specialty pharmaceutical company LEO Pharma today announced that findings from a Phase III study evaluating PEP005 (ingenol mebutate) Gel 0.05% to treat actinic keratosis (AK), a common pre-cursor to skin cancer, were presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) (Scientific Session Poster Discussion: P105). Results from REGION-I demonstrated treatment with PEP005 Gel once daily for 2 consecutive days.
The Georgia Institute of Technology and Micron Biomedical have been awarded $2.5 million in grants from the Bill & Melinda Gates Foundation to advance the development of dissolvable microneedle patches for polio immunization. The patches will be studied to evaluate their potential role as part of the worldwide efforts to eradicate polio.
Leaders in healthcare and the medical technology industry will bring you an in-depth look at Connected Health as emerging solutions can create real time feedback loops between patients and providers, whether in a hospital or clinic, at home, in the workplace or on the go.
Researchers have developed a three-dimensional 'organ on a chip' which enables real-time continuous monitoring of cells, and could be used to develop new treatments for disease while reducing the number of animals used in research.
Geron Corporation today announced the presentation of data from the clinical trial of imetelstat (GRN163L), the company's telomerase inhibitor drug, in combination with paclitaxel and bevacizumab in patients with breast cancer at the 2010 American Society of Clinical Oncology annual meeting in Chicago.
› Verified 3 days ago
Dr. Brian Christopher Cambi, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 333 Cedar St, Dcb 3, New Haven, CT 06510 Phone: 203-785-4129 Fax: 203-737-2437 | |
Ms. Maryam Gondal, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 330 Cedar Street, Bb 114, New Haven, CT 06510 Phone: 203-785-4184 | |
Matthew Joseph Mcconnell, M.D. Nephrology Medicare: Medicare Enrolled Practice Location: 333 Cedar St, Ynhh Internal Medicine-gi,section Of Digestive Diseases, New Haven, CT 06510 Phone: 203-785-7012 | |
Marie Anjeliese Rodriguez, Nephrology Medicare: Medicare Enrolled Practice Location: 20 York St, New Haven, CT 06510 Phone: 203-688-4242 | |
Dr. Margaret M Xu, MD Nephrology Medicare: Medicare Enrolled Practice Location: 20 York St, New Haven, CT 06510 Phone: 203-688-4242 | |
Carola Marte, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 1450 Chapel St, Haelen Center, New Haven, CT 06511 Phone: 203-789-4135 Fax: 203-867-5241 | |
Jeanette M Tetrault, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1 Long Wharf Dr, New Haven, CT 06511 Phone: 203-781-4600 Fax: 203-781-4624 |